Standout Papers

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of... 2015 2026 2018 2022 371
  1. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers (2015)
    Luisa Carbognin, Sara Pilotto et al. PLoS ONE

Immediate Impact

1 by Nobel laureates 13 from Science/Nature 56 standout
Sub-graph 1 of 23

Citing Papers

Probiotic neoantigen delivery vectors for precision cancer immunotherapy
2024 StandoutNature
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
5 intermediate papers

Works of Matteo Brunelli being referenced

PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non–Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs
2018
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
2015 Standout
and 2 more

Author Peers

Author Last Decade Papers Cites
Matteo Brunelli 4975 3398 2419 374 8.0k
Chin‐Lee Wu 2757 4149 2004 246 8.3k
Ming Zhou 6988 4364 1708 206 10.0k
Sven Perner 6893 6519 3091 264 12.8k
Hikmat Al‐Ahmadie 3282 3232 2201 254 8.3k
Isabell A. Sesterhenn 5454 4134 2263 210 10.9k
Arne Warth 4130 2491 3100 227 8.5k
Yoshihiro Matsuno 5501 2623 5119 377 12.7k
Rohit Mehra 8057 7080 2662 207 13.4k
Puay Hoon Tan 2073 2559 2557 327 9.1k
Mitchell C. Benson 8505 3887 2794 267 13.1k

All Works

Loading papers...

Rankless by CCL
2026